A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.
Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources
University Hospital Cologne: Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer
A retrospective study conducted at University Hospital Cologne compared two criteria for assessing therapeutic response to immunotherapy: iRECIST and…
Developing Standardized Reporting Templates for Sarcomas: Insights from Prof. Dr. Wolfgang Kunz
Sarcomas are a rare and heterogeneous group of malignant tumors that pose significant challenges in both diagnosis and treatment. Within the framework…
Standardized Reporting Template for Sarcomas in the BZKF BORN-Project: Interview with Prof. Dr. Wolfgang Kunz of LMU Munich
Sarcomas are a rare and highly diverse group of malignant tumors that affect both soft tissue and bones, posing significant challenges due to their…